Answers are grounded in this paper and cite their sources.
Abstract ID 95893 Poster Board 034 Background: The widely used botanical dietary supplement goldenseal is an established clinical inhibitor of cytochrome P450 (CYP) 3A activity, as evidenced by a 40-50% increase in the area under the plasma concentration vs. time curve (AUC) of the CYP3A probe drug midazolam after oral administration. Our recently observed lack of change in midazolam half-life further suggested that the interaction occurs primarily in the intestine. We next developed and verified a physiologically based pharmacokinetic (PBPK) model of the goldenseal-midazolam interaction to elucidate the mechanism of CYP3A inhibition (reversible vs. time-dependent) and anatomical site of the interaction (intestine vs. liver). Simulations indicated that the primary mechanism involves time-dependent inhibition of CYP3A in the intestine. Clinical verification that the intestine is the primary site of the interaction would enhance the robustness of this PBPK model. The objective of this study was to compare the pharmacokinetics of intravenously administered midazolam (to bypass first-pass metabolism) between the absence and presence of goldenseal. Methods: Adult volunteers (n = 22) participated in this 3-arm crossover study. Midazolam (0.5 mg) was administered intravenously alone (baseline), after a single oral dose (3 g) of goldenseal (acute), and after self-administration of goldenseal (1 g 3x daily) for 27 days (chronic). Blood (5 mL) was collected before and from 0.083-24 hours post-midazolam administration. Plasma was harvested and analyzed for midazolam and the primary metabolite, 1'-hydroxymidazolam, using a validated LC/MS/MS method. The pharmacokinetics of each analyte were determined via noncompartmental analysis methods using Phoenix WinNonlinTM (v8.1). Results: The geometric mean plasma concentration vs. time profile for both midazolam and 1'-hydroxymidazolam after intravenous administration of midazolam were essentially superimposable, regardless of goldenseal exposure (Figure 1). The geometric mean ratio (GMR) [90% confidence interval] of midazolam AUC in the presence to absence of goldenseal was 1.05 [0.87-1.23] and 0.97 [0.81-1.13] after acute and chronic goldenseal, respectively. Corresponding values for half-life were 0.98 [0.84-1.12] and 1.02 [0.88-1.16], respectively and for 19-hydroxymidazolam AUC were 1.03 [0.91-1.15] and 1.04 [0.70-1.38], respectively. The GMR of the 1'-hydroxymidazolam/midazolam AUC ratio was 1.16 [0.92-1.40] and 1.09 [0.85-1.33] after acute and chronic goldenseal, respectively. Conclusions: The lack of change in the pharmacokinetics of midazolam and 1'-hydroxymidazolam between baseline and goldenseal exposure, whether goldenseal was administered acutely or chronically for 27 consecutive days, confirmed that the goldenseal-midazolam interaction occurs primarily in the intestine. These novel observations further verify the PBPK model developed for this natural product-drug combination. This more robust model could be applied to other oral CYP3A substrates that may be co-consumed with goldenseal (e.g., calcium channel blockers, HCV and HIV protease inhibitors, statins), as well as various specific populations (e.g., hepatically impaired, renally impaired, pediatrics, pregnancy), to better predict interaction risks and manage pharmacotherapeutic regimens. Supported by the National Institutes of Health (U54 AT008909).
No takes yet. Share an insight, caveat, or question.
Hao et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: